Skip to content

Professor Matthew Wood

Board Observer

Matthew is Professor of Neuroscience and Deputy Head of the Medical Sciences Division at Oxford University and directs the Laboratory of RNA Biology and Neuromuscular Disease. Matthew is also a pioneering international leader in the field of exosome biology, publishing in Nature Biotechnology in 2011 the landmark discovery that exosomes could be developed into a therapeutic drug modality. Matthew has continued his pioneering work in the exosome field and is one of the co-founders of Evox Therapeutics. Matthew is also a world expert in the field of oligonucleotide therapies and co-leads a major international translational medicine collaboration (MDEX Consortium) that helped develop eteplirsen, the first-ever treatment for Duchenne muscular dystrophy. Matthew is a Director of Oxford University’s technology transfer organisation (Oxford University Innovation) and is also a Founder and Director of PepGen Ltd., an Oxford-based start-up biotech company. He also serves on the Scientific Advisory Board of Sarepta Therapeutics. Matthew graduated in Medicine from the University of Cape Town, working in clinical neuroscience before gaining a doctorate in Physiological Sciences from Oxford University.